Navigation Links
Epilepsy Therapy Project Announces "Shark Tank" Competition to Identify the Most Innovative, New Products for People with Epilepsy
Date:10/20/2011

WASHINGTON, Oct. 20, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures and the parent organization of epilepsy.com, today announced a "Shark Tank" competition and is now inviting entries that represent the most innovative ideas in epilepsy treatment and care. The winner of the 2012 Shark Tank competition will receive national recognition and a cash award supporting the development and commercialization of an important new product, technology or therapeutic concept. Epilepsy and seizure conditions affect more than 60 million individuals from infants and adults to accident victims and war veterans suffering from head injuries.

The top finalists will present their product concepts or therapeutic candidates at the Epilepsy Pipeline Update Conference in San Francisco on February 2, 2012.  The winning entry will be selected by a panel of judges representing physicians and scientists, corporate executives, industry investors, people with epilepsy and their family members. The project deemed to be the most innovative will be announced at the conclusion of the conference, and the winner will receive a $50,000 grant to accelerate the idea towards improving the quality of life of people with epilepsy. Finalists may be eligible for a travel stipend to attend the conference and will receive free conference registration. For more information and instructions on submitting a letter of intent, please visit http://www.epilepsy.com/sharktankguidelines or contact sharktank@epilepsytherapyproject.org.  

How to Submit Your Idea

Applicants must provide a letter of intent outlining their project goals and the near-term potential benefit to people with epilepsy, as well as the
'/>"/>

SOURCE Epilepsy Therapy Project
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Editor-in-Chief of Elseviers Epilepsy & Behavior presented with Ambassador for Epilepsy Award
2. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
3. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
4. Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
5. Texas Childrens Hospital Pioneers Use of MRI-guided Laser Surgery for Revolutionary New Epilepsy Treatment
6. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
7. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
10. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
11. Cyberonics Announces Epilepsy Technology Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 Tandem Diabetes Care®, ... and manufacturer of the t:slim® Insulin Pump, today reported its ... In comparing the second quarter of 2014 to ... percent to $10.3 million from $5.5 million , t:slim ... pumps In comparing six months ended June 30, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
...   OncoSec Medical Incorporated (OTCBB:ONCS), which is ... therapies to treat solid tumor cancers, today announced ... company,s Phase II Merkel cell carcinoma clinical trial, ... The Journal Newspaper.    (Logo: ...
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), ... commercialization of innovative therapies for the treatment of acute ... in a Phase 3 study for ARX-01, the Sufentanil ... This first ARX-01 Phase 3 study is a randomized, ...
Cached Medicine Technology:OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 2OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 3OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 2AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 3AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 5
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- Almost 140 people die every year in ... States. But there are several simple ways ... prevention coordinator at Cincinnati Children,s Hospital Medical Center,s ... center news release. "As families begin to ... for parents and children to go over school ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... subjects that they were actually losing weight.,// ,Researchers belonging ... believe that they were losing weight when in reality they ... which gave the illusion that their hands were moving inward. ... creating a new body image. , The stimulators used ...
... to new research, elderly heart failure patients in United ... but lose that advantage over time.// ,Their study ... of Internal Medicine. ,Heart failure is the most ... older in both countries. ,The authors compared process ...
... have made the task of hasseled mothers easier by revealing ... foods even when in the womb. Making the task of ... they want their babies to when they are pregnant. ... of amniotic fluid a day and it is believed that ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... that the libido of a patient may be affected ... The secretion and creation of testosterone triggered by some ... of the patient. ,For most epileptics, however, treating ... a sensible approach, experts say. ,If no drugs ...
... to a latest survey, there is a steady decline in ... // . ,The findings were presented at the ... month by researchers from Cancer Research UK and the UK ... while cancer incidence rates have remained stable, there has been ...
Cached Medicine News:Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2
The Duran Flexible Annuloplasty System encompasses both performance and practicality....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: